<DOC>
	<DOCNO>NCT02598193</DOCNO>
	<brief_summary>This clinical study evaluate safety tolerability combination treatment nintedanib pirfenidone participant IPF . Eligible participant must receive pirfenidone least 16 week stable dose . Nintedanib add Day 1 study combination treatment IPF 24 week .</brief_summary>
	<brief_title>Safety Tolerability Study Pirfenidone Combination With Nintedanib Participants With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Participants pirfenidone least 16 week stable dose ( defined 16022403 milligram per day [ mg/day ] ) least 28 day start Screening ; dose must expect remain range throughout study . Documented diagnosis IPF , per Investigator per use criterion 2011 American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Latin American Thoracic Association guideline . Participants percent predict forced vital capacity ( FVC ) equal ( &gt; = ) 50 % percent predict carbon monoxide diffuse capacity ( DLco ) &gt; =30 % Screening . For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use two adequate method contraception , include least one method failure rate le ( &lt; ) 1 % per year , treatment period least 3 month final Followup Visit . For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure agreement refrain donate sperm . Participants clinical evidence active infection . Participant new ongoing moderate severe adverse reaction consider Investigator related pirfenidone , pirfenidone treatment interruption 28 day start Screening . Any condition likely result death 12 month start Screening . Lung transplantation anticipate planned significant surgical intervention . Known hypersensitivity active substance excipient either pirfenidone nintedanib . Severe hepatic and/or renal impairment . History gastrointestinal ( GI ) tract perforation , unstable deteriorate cardiac pulmonary disease ( IPF ) , long QT syndrome , alcohol substance abuse , use tobacco product etc . Bleeding risk . Use Cytochrome P450 ( CYP ) 1A2 ( CYP1A2 ) inhibitor ( example , fluvoxamine , enoxacin ) and/or use inhibitor Pglycoprotein ( example , ketoconazole , erythromycin ) CYP3A4 ( example , ketoconazole , erythromycin ) inducer ( example , rifampicin , carbamazepine , phenytoin , St John 's wort ) 28 day start Screening . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>